Premium
Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment
Author(s) -
Uemura Hiroji,
Ishiguro Hitoshi,
Kubota Yoshinobu
Publication year - 2008
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01937.x
Subject(s) - angiotensin ii receptor type 1 , medicine , prostate cancer , angiotensin ii , renin–angiotensin system , angiogenesis , receptor , angiotensin receptor , cancer , pharmacology , endocrinology , prostate , cancer research , blood pressure
Although a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors has been reported, the molecular mechanisms have not been elucidated. It is known that angiotensin‐II (Ang‐II) plays a fundamental role not only as a vasoconstrictor in controlling blood pressure and electrolyte and fluid homeostasis, but also as a mitogenic factor through the Ang‐II type‐1 (AT1) receptor in cardiovascular cells. Interestingly, there is increasing evidence that the renin‐angiotensin system (RAS) is implicated in the development of various cancers. As we previously reported, AT1 receptor blockers (ARBs), a class of antihypertensive agent, have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review provides an insight into the key role of Ang‐II and the AT1 receptor, and the possibility of ARBs for molecular targeting of mitogenesis and angiogenesis in prostate cancer.